Can buspirone (Buspar) cause supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Buspirone Does Not Cause SVT

Buspirone (Buspar) is not known to cause supraventricular tachycardia (SVT). Based on the FDA drug label and available evidence, buspirone does not have a documented association with triggering SVT episodes.

Evidence from FDA Drug Label

The FDA-approved prescribing information for buspirone lists cardiovascular adverse events comprehensively 1. Notably absent from this list is any mention of SVT or supraventricular tachycardia. The cardiovascular effects documented include:

  • Frequent (≥1/100 patients): Nonspecific chest pain, tachycardia/palpitations (1%)
  • Infrequent (1/100 to 1/1000 patients): Syncope, hypotension, hypertension
  • Rare (<1/1000 patients): Cerebrovascular accident, congestive heart failure, myocardial infarction, cardiomyopathy, bradycardia

The reported "tachycardia/palpitations" at 1% incidence is non-specific and occurred at the same rate as placebo, suggesting it is not a drug-induced effect 1.

Cardiovascular Mechanism of Buspirone

Research evidence helps explain why buspirone would not be expected to cause SVT:

  • Buspirone acts as a partial 5-HT1A agonist and affects dopaminergic and noradrenergic systems 2, 3
  • In healthy subjects, buspirone actually decreases heart rate and systolic blood pressure through parasympathetic activation 2
  • Animal studies show buspirone produces bradycardia (slowing of heart rate) rather than tachycardia in most circumstances 4, 3
  • The drug increases peripheral sympathetic activity but this manifests as increased catecholamines with paradoxical heart rate reduction 2, 3

Clinical Context

Important distinction: While buspirone can cause non-specific palpitations (subjective awareness of heartbeat), this is fundamentally different from SVT, which is a specific arrhythmia requiring AV nodal or atrial tissue for initiation and maintenance 5.

Common Pitfalls to Avoid:

  1. Do not confuse palpitations with SVT: Palpitations are a symptom that can occur without any arrhythmia
  2. Do not attribute pre-existing SVT to buspirone: SVT has a prevalence of 0.2% in the general population and affects 168-332 per 100,000 individuals 6; temporal association does not equal causation
  3. Consider alternative explanations: Anxiety itself (the condition being treated) commonly causes palpitations and can trigger SVT episodes through increased sympathetic tone

Safety Profile

Buspirone has an excellent cardiovascular safety profile 7. Meta-analysis of safety data shows no significant cardiac conduction abnormalities or arrhythmogenic potential at therapeutic doses. The drug does not prolong QT interval or widen QRS duration—factors that would increase arrhythmia risk 7.

Bottom line: If a patient on buspirone develops SVT, investigate other causes including underlying cardiac substrate, electrolyte abnormalities, stimulant use, or the natural history of their arrhythmia rather than attributing it to buspirone.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.